Publications
- Erlotinib in the treatment of advanced non-small cell lung cancer - present experience and results in the Czech Repuiblic2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?2022 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?2022 | Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment2021 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Entrectinib in the treatment of patients with ROS1‑positive advanced non‑small cell lung cancer2021 | Publication without faculty affiliation
Loading network view...